Dr Willem J. van der Giesen, MD, PhD from the Erasmus University Medical Center will make a presentation on next generation drug eluting stents, in which he will discuss the results of the 4 week porcine study, performed by the Department of Cardiology, Thoraxcenter, Erasmus University Medical Center in the Netherlands, an independent research organization.
The study indicated that three variations of MIVT's Hydroxyapatite-based Drug-Eluting stents were at least as effective as, and in some cases, better than one of the worlds leading drug-eluting cardiovascular stents produced by Johnson & Johnson (Cypher(TM)). These results provided the necessary data to advance the technology to human studies.
Hydroxyapatite, unlike polymer coatings, is naturally derived and found in such hard tissues and bioceramic materials as human bone and teeth. Research has indicated that MIVT's HAp coatings do not trigger the various adverse and inflammatory reactions that are often associated with implantation of polymer-coated stents and other foreign substances.
HAp coatings are also expected to reduce the risk of thrombogenic (blood clotting) events attributable in some instances to polymer-coated stents. Some of the most recent information presented at various conferences estimated that thrombogenicity was identified in at least 20,000 cases of implanted drug-eluting stents to-date, resulting in approximately 8,000 premature deaths.
EuroPCR is a major European event based on the exchanged of scientific information and education for interventional cardiologists.
About MIV Therapeutics Inc.
MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents and a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. The Company's unique ultra-thin coating platform is derived from an organic material called hydroxyapatite (HAp) which has demonstrated excellent safety and biocompatibility in vivo animal studies. Hydroxyapatite is a porous material that makes up the bone mineral and matrix of teeth and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug eluting technologies based on Hydroxyapatite could also provide an attractive alternative to current polymer-based drug eluting coatings on the stent market, which have been associated with undesirable medical effects. The Company's drug eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIVT has a Collaborative Research Agreement (CRA) with the University of British Columbia and has received Government grant for its research program on the "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents," under the National Research Council-Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship, the Company is expected to complete its drug-eluting research and development program and to reach product commercialization stage.
For more information, please visit http://www.trilogy-capital.com/tcp/mivt/w ebsite.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is traded on the Frankfurt, Germany, stock exchange under the symbol MIV.
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "proposed," "expected," "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties including, without limitation, the potential for the unsuccessful closing by the Company of its Vascore acquisition, together with the raising of funding sufficient to continue with its operations and those contemplated by the Company as a consequence thereof, and the ability of the Company to raise sufficient funding and to continue to develop its various business interests as presently contemplated. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
MIV Therapeutics Inc.
Investor Relations, 604-301-9545, x14
Trilogy Capital Partners
Ryon Harms, Toll-free: 800-592-6067